Compare stocks

SOLV vs TLSI

Solventum Corporation and TriSalus Life Sciences, Inc. Common Stock

Compare the businesses

Solventum Corporation

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wrap, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. Its Dental Solutions segment provides a suite of dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions and services for health care systems, such as computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. Its Purification and Filtration segment provides purification and filtration technologies comprising filters, purifiers, cartridges, and membranes. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is based in Maplewood, Minnesota.

Open SOLV dashboard ↗

TriSalus Life Sciences, Inc. Common Stock

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Open TLSI dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗